source
- Novartis signs up to $3.2 billion deal with Korea's Alteogen for subcutaneous drug delivery technologyNovartis has entered an option and license agreement with Korean biotech Alteogen to use its ALT-B4 subcutaneous delivery platform, a partnership that could be worth up to $3.2 billion if all optio…
- H1 partners with Novo Nordisk to build AI-driven data foundation for clinical developmentClinical trials are becoming more complex and data‑heavy, but decision‑making processes have not kept pace. H1 and Novo Nordisk are collaborating to address this gap. Novo Nordisk’s StudyHub links…